ABSTRACT
INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Since most patients with CF develop progressive pulmonary disease, measures of pulmonary involvement, in particular the forced expiratory volume in one second (FEV 1 ), have been used as markers of disease severity and to predict survival [1] [2] [3] . However, considerable heterogeneity exists in prognosis and severity, even among patients of the same genotype, suggesting that genetic modifiers may play a role 4 .
The study of gene modifiers in monogenic disorders requires rigorous phenotyping, and inadequate characterization of the phenotype is a well-recognized limitation of case-control genetic association studies [5] [6] [7] [8] . In CF, pulmonary phenotyping is complex, since the progression of lung disease is likely multi-factorial, and is multi-phasic or nonlinear for some patients 9, 10 .
One specific type of case-control genetic association study design compares patients at the extremes of phenotype, i.e., those with severe vs. mild disease, because it provides additional power to detect gene modifiers 11 . In such studies, it is particularly important to be able to accurately identify patients at the extremes of phenotype. In this paper, we investigate approaches to classifying severity of disease when longitudinal lung function measures are available, and compare them using data from the Gene Modifier Study (GMS), a large multicenter study of genetic modifiers of CF lung disease 12 . The goal of the GMS is to examine the association of genetic polymorphisms with pulmonary phenotype in ∆F508 homozygotes by comparing patients with "severe" vs. "mild" pulmonary disease.
METHODS (534 words)

Design and enrollment criteria in the GMS
Patients were initially enrolled into "severe" or "mild' groups, based on current age and most recent FEV 1 (% pred.), while clinically stable 12 . The severe group included patients age [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] years and the mild group was divided into young and older subgroups (ages 15-28 and ≥ 29 years, respectively). Enrollment by severity group was based on age-specific cutoff values for FEV 1 (% pred; see online supplement), derived approximately from quartiles of lung function for patients age < 34 years in the U.S. Cystic Fibrosis Foundation Registry 13 . Patients age ≥ 34 years were considered "mild" regardless of their FEV 1 , on the basis of survival. All available spirometric data in the previous five years for each patient were collected, including pre-and post-bronchodilator values, regardless of the patient's status with respect to acute illnesses.
Analyses used the pre-bronchodilator value, if available (97% of measurements). Otherwise, the post-bronchodilator value was used. Percent predicted values for spirometry measurements were calculated using Knudson equations 14 .
Characterization of longitudinal patterns of FEV 1 in individual patients
Longitudinal FEV 1 data were analyzed using a mixed model, assuming the mean FEV 1 (%pred.) follows a linear regression vs time for each patient with random patient-specific slope and intercept, with a separate population regression line for each of the three severity groups (Appendix A). The mixed model provided estimates of the mean intercept and slope by severity group, as well as estimates of patient-specific slopes and intercepts (empirical Bayes estimates).
We first reexamined the initial classification of each patient, which was based on their single Receiver operating characteristics (ROC) curves 15 were used to evaluate and compare several patient-specific summary indices in order to assess which were best at discriminating between mild and severe groups. The summary indices included mixed model and least-squares estimates of patient-specific rates of decline in FEV 1 (% pred.) and levels of FEV 1 (% pred.) at ages 5-25 years.
We also predicted age at death based on a model relating survival to longitudinal lung function, using parameters estimated from an analysis of an external dataset of n=188 homozygous ∆F508 patients 2 ; this estimate of age at death was also evaluated as a severity measure.
Analyses were performed using SAS version 9.1 16 . Data are presented as mean ± standard deviation. Between-group comparisons were made using chi-square tests for categorical variables and using one-way analysis of variance for continuous variables.
RESULTS
Screening for outliers and characterization of severity groups
The age-specific boundaries of FEV 1 (% pred.) at enrollment, used for initial classification by severity, are shown in Figure 1 ; the specific cutoffs used at each age are provided in the online supplement.
Mixed model estimates of slope and intercept (at birth, i.e., age 0 yrs) of the regression of FEV 1 (% pred.) vs. age were used to estimate the level of 
Ability of measures of disease severity to discriminate between extremes of phenotype
Patient-specific summary measures, derived from the patients' longitudinal data, were evaluated in their ability to distinguish between severe vs. mild groups. Discriminating ability was ascertained using the area under the receiver operating characteristic (ROC) curve, which plots sensitivity vs. 1-specificity of the index as the threshold value (cutpoint) used for classification is varied. The ROC area ranges from 0.5 for an index with no discriminating ability to 1.0 for an index able to discriminate perfectly (i.e., where there is no overlap in distribution between mild and severe groups).
One possible index of phenotype is the predicted probability of being severe from the logistic regression of disease severity on age and estimated FEV 1 (% pred.) at enrollment, i.e., the method used to identify outliers in this study. Because the severity groups are defined by this method, however, it achieves perfect separation by definition, and thus its performance cannot be directly assessed in this study, Instead we focus on other indices, such as level of FEV 1 at a fixed age, patient-specific slope of FEV 1 , and estimated survival percentile. Results (Table 2) are presented based on analysis of all 802 patients, and also for the subset of 553 patients who had five years of pulmonary function measurements with at least one measurement in each year, in order to reduce the confounding influence of variability in length of follow-up. Histograms of selected indices by severity group are displayed in Figures 3a-d.
FEV 1 (% pred.) at a fixed age. We examined the discriminating ability of the patient's estimated level of FEV 1 (% pred.), at ages 5, 10, 15, 20, and 25, obtained using both mixed model as well as least-squares estimates of patient-specific slopes and FEV 1 levels ( Table 2 ). Using mixed model estimates, optimal discrimination is achieved using estimated indicates that there is little overlap between severe and mild groups with respect to this measure.
As indicated by the ROC areas in Table 2 , least-squares estimates of slopes or levels of FEV 1 (% pred.) do not discriminate between groups as well as do the mixed model estimates. It is well-known that least-squares slopes can be highly variable and imprecise for patients with few data points over a short time period [17] [18] [19] [20] . When restricted to subjects with five years of data, the discriminating ability of least-squares estimates improved, but mixed model estimates still outperformed the least-squares estimates ( Table 2 ). Logistic regression on FEV 1 slope and intercept. Because each patient's regression line is fully characterized by its intercept and slope, another approach to developing a classification of mild vs. severe patients is to fit a logistic regression of phenotype (severe vs. mild) using both estimated FEV 1 intercept at age 0, and FEV 1 slope as predictors (see Appendix B). When this approach was used, the ROC area was .995 (Table 2) . It can be shown (Appendix B) that the ROC area of this approach using the intercept and slope will be greater than or equal to the ROC area based on using estimated FEV 1 at any single fixed age. Also, provided the logistic regression coefficient of the intercept is nonzero (indicating that the FEV 1 intercept contributes to prediction in addition to the FEV 1 slope), use of the intercept and slope to predict severity is equivalent to using estimated level of FEV 1 at a single 'optimal' age, estimated to be 19.6 years in the GMS study (Appendix B). The optimal age, 19.6 years, closely matches the empirically determined optimal age of 20 in Table 2 , and the ROC area based on the FEV 1 at age 19.6 (. 995) is identical to that obtained using the intercept and slope.
Predicted age at death obtained from a model relating survival time to FEV 1 . A model relating survival to FEV 1 (% pred.), using estimates of parameters obtained by fitting it to an external data set of 188 CF ∆F508 homozygous patients 2 , was applied to the GMS patient data to obtain a prediction of age at death. The prediction for each individual is expressed as a population percentile ranging from 0 to 1; thus, a predicted age at death equal to the median for the ∆F508
CF population would result in the percentile equaling .50, and lower (higher) values of the percentile represent worse (better) survival. Because the original parameter estimates from this model were obtained by fitting it to best yearly measures of FEV 1 , we also used best yearly measures from the GMS data. The means and standard deviations of the estimated percentiles of predicted age at death were 0.37 ± 0.14, 0.81 ± 0.09, and 0.78 ± 0.06 for the severe, young mild, and older mild groups, respectively. Figure 3d shows distributions of the estimated survival percentiles. This approach provided an ROC curve area of .994, providing essentially the same discrimination between groups as the FEV 1 (% pred.) at the optimal age of 19.6 years.
Comparison of estimates obtained using all vs. best yearly FEV 1 values
When (% pred.) at age 20 was used both as a continuous phenotype and also dichotomized as <68% vs, ≥ 68%, to examine the association of severity of pulmonary disease with the TGFB1 codon 10 genotype.
The two approaches that best discriminated between severe and mild groups as defined in the GMS patients were 1) logistic regression using intercept and slope of FEV 1 (% pred.) (mixed model estimates) as predictors, and 2) the predicted survival age percentile. ROC curve areas for these two approaches were essentially the same, (.995 and .994, respectively). Note that, although we used intercept at birth and slope of FEV 1 in the model, the use of estimated FEV 1 at any other age along with slope provides an equivalent predictive model. We show that prediction of severity group using the logistic regression on slope and intercept is equivalent to using estimated FEV 1 at age 19.6 as a single summary index, and that the estimated level of FEV 1 at this 'optimal' age will outperform FEV 1 estimated at other ages. Thus, the first approach can be simplified by using estimated FEV 1 at age 20 as a single summary index. An advantage of this approach is its simplicity. A potential drawback (discussed below) is that the mixed model estimates of FEV 1 at a fixed age and slope are not independent of the group to which the subject was initially assigned, because the mixed model estimates are 'shrunken' toward the mean of the group to which the patient was initially assigned. While having the disadvantage of being more complex to calculate, the survival percentile has several advantages: 1) it is estimated using only the subject's actual FEV 1 data and attained age, and is thus independent of the initial group assignment, and 2) it is calculated using parameters estimated externally to the sample of 802 subjects. The congruence of two very different methods (logistic regression based on slope and intercept, and survival percentile) in predicting severity was encouraging in the GMS, and supports the validity of using either measure as a continuous severity measure.
Other summary indices such as estimated level of FEV 1 (% pred.) at age 5, 10, 15, 20, and 25 years and FEV 1 slope did not discriminate between severity groups as well as did estimated FEV 1 at age 20 or the estimated survival age percentile. Notably, the results indicate clearly that the estimated slope of FEV 1 (% pred.), whether estimated using the mixed model or leastsquares, does not discriminate between mild and severe groups nearly as well as the patient's level of FEV 1 (% pred.) at 20 years, which is a function of both the patient's estimated level of FEV 1 (intercept) and slope. In an analysis using mixed models to compare intercepts and rates of decline in FEV 1 (% pred.) of CF patients, grouped by age at death, Corey et al 3 similarly
showed that patients who died earlier had both lower intercepts as well as more negative slopes of FEV 1 (% pred.), supporting the notion that severity is manifested both through the initial level as well as the slope of FEV 1 (% pred.). The mixed model estimates we evaluated were obtained from a model with severity group included in the model; thus, the intercept and slope estimates for each patient are shrunken toward the group mean to which the patient is initially assigned, rather than toward the overall mean. An implication is that the estimate for an individual patient is influenced to some extent by the group to which the patient was initially assigned, particularly for patients with few points over a short age range. Thus, the mixed model estimates may appear to be somewhat better discriminators between mild and severe patients than they actually are, particularly when patients with short follow-up times are included. For example, among patients with FEV 1 measurements in five consecutive years of follow-up, the area under the ROC curve for a logistic regression using the individual estimates of slope and intercept obtained under a mixed model not including group as a fixed effect was .969, compared to an area of .994 for estimates obtained from a model with group included.
Mekus et al. 21 describe an alternative method for classifying severity of pulmonary disease in CF patients by calculating age-specific percentiles of FEV 1 (% pred.) in CF patients, as determined from analysis of data in the European CF Registry. Using equations provided to us (personal communication, F. Mekus-Stanke) we calculated the percentile of FEV 1 (% pred.) for GMS patients age 30 and less, the age range for which the calculations apply. Because this approach was originally developed using only a single FEV 1 , we adapted it to our longitudinal data by using the mixed model estimate of level of FEV 1 (% pred.) at the patient's final age, and excluded patients > 30 years of age. The estimated ROC area for this index was 1.00, indicating complete separation between the groups. This is not unexpected, however, since the mild and severe groups in the GMS study, by definition, show complete separation based on FEV 1 (% % predicted for CF patients using data from the US National CFF Registry (1994-2001) for ages 6-40 years in graphical form, which would allow similar percentiles to be calculated using data from cystic fibrosis patients in the United States.
A limitation of the approach we have taken is that there is some circularity involved in defining severity, then comparing candidate severity measures against the groups so defined. The way severe and mild groups were initially defined precluded a 'fair' comparison of the discriminating ability of the logistic regression using last predicted FEV 1 % predicted and age are predictors, or of the Mekus approach, both of which result in 100% discrimination between groups in this dataset. However, the survival prediction, which is independent of the initial group assignment and estimated based on externally estimated parameters, yielded similar discrimination to the optimal approach using the patient's slope and intercept in a logistic regression model.
In conclusion, we have described an approach for enrolling and phenotyping cystic fibrosis patients with severe and mild disease. Patients were enrolled initially based on age-specific cutoffs for their current FEV 1 , and this classification of disease severity was confirmed after analysis of their longitudinal data in the five years preceding enrollment. Only 18/820 (2%) of patients were deemed to be misclassified according to extremes of phenotype (severe vs. mild) based on the single initial FEV 1 , when all longitudinal data were examined. Subsequent analyses suggest that the estimated FEV 1 (% pred.) at age 20, calculated from longitudinal data, is an accurate discriminator between patients with severe and mild disease, and can be linked to longterm outcome, i.e., duration of survival, which is ultimately the most important phenotypic outcome measure for testing association of gene modifiers. Estimates of FEV 1 (% pred.) at age 20 from a longitudinal study may also be useful as a continuous index of disease severity, as evidenced by the approach recently utilized in the GMS 12 .
Appendix A. Mixed Effects Model
Let y ij be the jth measurement of FEV 1 (% pred.) obtained on the ith subject, for i=1,…,n i .
Define the group indicator variables G 1i =1 if subject i is in the older mild group, and 0 otherwise, and G 2i =1 if subject I is in the severe group, and zero otherwise. The mixed model can be written as: 
